Summary: Nigeria now has access to Lenacapavir, a revolutionary HIV prevention injection administered only twice yearly. Learn how this breakthrough could transform HIV prevention across the country.
Nigeria has just scored a major win in the fight against HIV. The country has officially received Lenacapavir, a groundbreaking long-acting injection that could change the game for HIV prevention as we know it.
The Coordinating Minister of Health and Social Welfare, Professor Ali Pate, approved the introduction of this breakthrough medication with backing from the Global Fund—a move that health experts are calling a watershed moment for Nigeria’s battle against the HIV epidemic.
What Makes Lenacapavir Special?
Unlike the daily pills many people currently take to prevent HIV infection, Lenacapavir is an injection you only need to take twice a year. Yes, you read that right—just two injections annually instead of swallowing pills every single day.
This is designed for pre-exposure prophylaxis (PrEP), which means it’s meant for people who are at risk of contracting HIV but don’t currently have the virus. The injection provides a much more convenient option, especially for Nigerians who find it challenging to remember daily medication or maintain a consistent routine.
Why This Matters for Nigeria
Health experts believe Lenacapavir could dramatically improve treatment adherence. Let’s be honest—taking medication every day without fail isn’t easy for everyone. Life happens. You travel, you forget, you run out of pills. With a twice-yearly injection, these challenges become much less significant.
Dr. Adebobola Bashorun, the National Coordinator of the National HIV Viral Hepatitis and STDs Control Programme (NASCP), emphasized that Lenacapavir’s arrival demonstrates Nigeria’s dedication to using proven, cutting-edge innovations to speed up progress in controlling the epidemic.
“Expanding prevention options and strengthening service delivery will help reduce new infections and improve health outcomes across the country,” Bashorun stated. He assured Nigerians that NASCP, working with partners and stakeholders, will ensure the medication is rolled out safely and properly integrated into Nigeria’s national HIV prevention programmes.
How Affordable Will It Be?
Here’s more good news: Lenacapavir is expected to cost approximately $40 per person annually in Nigeria and 119 other low- and middle-income countries. This pricing comes through voluntary licensing agreements with generic pharmaceutical manufacturers, making it accessible to more people who need it.
While ₦40,000-₦50,000 per year (depending on exchange rates) may still seem like a lot to some Nigerians, it’s significantly cheaper than many other HIV prevention options, especially when you consider that you only need two doses per year instead of 365 pills.
A Step Closer to Ending HIV
Health officials say that bringing Lenacapavir to Nigeria moves the country significantly closer to achieving the goal of ending HIV as a public health threat.
Nigeria has one of the highest HIV burdens in the world, so innovations like this aren’t just welcome—they’re absolutely necessary. By giving people at risk more options that actually fit into their lives, we stand a much better chance of preventing new infections and protecting more Nigerians.
The introduction of Lenacapavir represents hope, progress, and Nigeria’s commitment to ensuring that every citizen has access to modern, effective healthcare solutions in the fight against HIV/AIDS.
For more information about HIV prevention services and where to access Lenacapavir when it becomes available, Nigerians can contact their nearest government health facility or reach out to NASCP through the Federal Ministry of Health.
Check buzzUp9ja for more updates
Be the first to comment